Magnetic Affinity Nanoparticles for Bevacizumab Adsorption

GR BARREDO VACCHELLI; SL GIUDICESSI; F ALBERICIO; O CASCONE; SA CAMPERI

Proceedings of the 36th European and the 12th International Peptide Symposium

European Peptide Society

Año: 2022; p. 127 - 129

The vascular endothelial growth factor (VEGF) stimulates tumor angiogenesis by targeting its receptor(VEGFR). The IgG monoclonal antibody bevacizumab, produced in CHO cells, is used for cancertreatment due to its capability of targeting the endothelial growth factor A (VEGF-A) and inhibitingangiogenesis. Bevacizumab purification step may account for as much as 70% of the totalmanufacturing cost because of the high purity necessary for its parenteral administration. Nowadays,its purification is achieved by protein A affinity chromatography (AC). However, protein A is a veryexpensive ligand and harsh elution conditions are required to recover bevacizumab from the ACcolumn, which can damage the mAb as well as the protein A ligand.Recently, we have reported a short peptide contained in VEGF that binds to bevacizumab withhigh affinity and selectivity and demonstrated that this peptide bound to agarose can be used to purifybevacizumab at a lower cost and no harsh elution conditions. However, conventionalchromatography requires a previous clarification step to avoid column clogging.Unlike conventional chromatography, magnetic nanoparticle (MNP) purification allows theextraction of the target directly from the cell culture without needing clarification steps. In thiswork, bevacizumab purification with MNP with a peptide ligand immobilized is assessed.